Data gathered: January 26
AI Stock Analysis - Dexcom (DXCM)
Analysis generated October 7, 2024. Powered by Chat GPT.
Dexcom, Inc. is a market leader in continuous glucose monitoring (CGM) systems for diabetes management. Founded in 1999 and headquartered in San Diego, California, Dexcom has focused on developing and marketing CGM devices for people with diabetes. The company's flagship product, the Dexcom G6, allows users to monitor their glucose levels in real time without the need for fingersticks. As a company that operates in the healthcare and medical technology sector, Dexcom is well-positioned to benefit from the increasing prevalence of diabetes worldwide and the shift towards more advanced, patient-friendly monitoring solutions.
Stock Alerts - Dexcom (DXCM)
 |
Dexcom | January 21 Over the past few months, there has been an downward trend in the business outlook. |
|
Dexcom | January 16 Price is up by 5.3% in the last 24h. |
|
Dexcom | January 16 Kevin Hern (member of U.S. congress) is selling shares |
|
Dexcom | January 13 Price is up by 5.5% in the last 24h. |
Alternative Data for Dexcom
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 281 | Sign up | Sign up | Sign up |
| Sentiment | 88 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,243,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | 62 | Sign up | Sign up | Sign up |
| Patents | 804 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 11,221 | Sign up | Sign up | Sign up |
| Facebook Followers | 195,247 | Sign up | Sign up | Sign up |
| Instagram Followers | 175,943 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 9 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 9,865 | Sign up | Sign up | Sign up |
| Twitter Followers | 8,828 | Sign up | Sign up | Sign up |
| Twitter Mentions | 20 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 41,800 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | 30 | Sign up | Sign up | Sign up |
| Business Outlook | 67 | Sign up | Sign up | Sign up |
| Linkedin Employees | 7,306 | Sign up | Sign up | Sign up |
About Dexcom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
| Price | $88.75 |
| Target Price | Sign up |
| Volume | 3,190,000 |
| Market Cap | $34.7B |
| Year Range | $64 - $130.84 |
| Dividend Yield | 0% |
| PE Ratio | 53.79 |
| Analyst Rating | 87% buy |
| Industry | Medical Devices |
In the news
 |
Janney Montgomery Scott LLC Increases Stock Position in DexCom, Inc. (NASDAQ:DXCM)January 26 - ETF Daily News |
|
2,762 Shares in DexCom, Inc. (NASDAQ:DXCM) Bought by Ballentine Partners LLCJanuary 26 - ETF Daily News |
 |
5 Key Insights On Dexcom’s Stelo & Abbott’s Lingo Glucose MonitorsJanuary 25 - Forbes |
|
Atomi Financial Group Inc. Increases Position in DexCom, Inc. (NASDAQ:DXCM)January 25 - ETF Daily News |
|
MassMutual Private Wealth & Trust FSB Boosts Stake in DexCom, Inc. (NASDAQ:DXCM)January 25 - ETF Daily News |
|
UMB Bank n.a. Purchases 758 Shares of DexCom, Inc. (NASDAQ:DXCM)January 24 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 994M | 707M | 594M | 135M | 237M | 0.450 |
| Q2 '24 | 1B | 710M | 627M | 144M | 245M | 0.430 |
| Q1 '24 | 916M | 678M | 562M | 146M | 190M | 0.320 |
| Q4 '23 | 1.03B | 696M | 657M | 256M | 261M | 0.500 |
| Q3 '23 | 970M | 638M | 623M | 121M | 247M | 0.500 |
Insider Transactions View All
| Leach Jacob Steven filed to sell 264,171 shares at $76.9. December 17 '24 |
| Sylvain Jereme M filed to sell 80,030 shares at $76.9. December 17 '24 |
| Stern Sadie filed to sell 70,768 shares at $76.9. December 17 '24 |
| Heller Bridgette P filed to sell 23,349 shares at $76.9. December 17 '24 |
| Stern Sadie filed to sell 71,192 shares at $74.7. November 22 '24 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Boston ScientificBSX |
$101.94 0% | 57 |
 |
Edwards LifesciencesEW |
$68.99 0% | 51 |
 |
Intuitive SurgicalISRG |
$584.05 0% | 79 |
 |
MedtronicMDT |
$90.19 0% | 47 |
 |
StrykerSYK |
$394.31 0% | 47 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Kevin Hern |
Jan 16, 25 | Sell | $50K - $100K |
| Ro Khanna |
Oct 8, 24 | Buy | $1K - $15K |
| Rohit Khanna Democrat |
Nov 8, 23 | Buy | $1K - $15K |
Read more about Dexcom (DXCM) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Dexcom?
The Market Cap of Dexcom is $34.7B.
What is Dexcom's PE Ratio?
As of today, Dexcom's PE (Price to Earnings) ratio is 53.79.
What is the current stock price of Dexcom?
Currently, the price of one share of Dexcom stock is $88.75.
How can I analyze the DXCM stock price chart for investment decisions?
The DXCM stock price chart above provides a comprehensive visual representation of Dexcom's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Dexcom shares. Our platform offers an up-to-date DXCM stock price chart, along with technical data analysis and alternative data insights.
Does DXCM offer dividends to its shareholders?
As of our latest update, Dexcom (DXCM) does not offer dividends to its shareholders. Investors interested in Dexcom should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Dexcom?
Some of the similar stocks of Dexcom are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.
.